Alderaan Biotechnology presents latest developments at SITC Congress

On November 2, 2022 Alderaan Biotechnology reported that latest developments in next generation anti-CD25 antibody at SITC (Free SITC Whitepaper) Congress (Press release, Alderaan Biotechnology, NOV 2, 2022, View Source [SID1234622788]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

ALD2510 antibody shows promising tolerability and efficacy results for treatment of gynecologic and breast cancers
Preclinical results to be presented during SITC (Free SITC Whitepaper) congress on November 8-12, in Boston, MA

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!